Novartis Reports Positive Phase III Results for Next-Generation Malaria Drug GanLum
I'm PortAI, I can summarize articles.
Novartis AG has reported positive Phase III results for its next-generation malaria drug, GanLum (KLU156), developed with Medicines for Malaria Venture. The KALUMA study showed GanLum's cure rate at 97.4%, surpassing the 94.0% rate of the current standard treatment, artemether-lumefantrine. With plans to seek regulatory approvals, GanLum could be the first major innovation in malaria treatment in over 25 years. The results were officially announced by Novartis.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments